RESEARCH - New data will help guide prescribing of Celebrex

[Guest guest]

New Data Will Help Guide Prescribing of Celecoxib CME/CE

News Author: Nainggolan

CME Author: Désirée Lie, MD, MSEd

Release Date: April 2, 2008; Valid for credit through April 2, 2009

Credits Available

From American College of Cardiology (ACC) 57th Annual Scientific Session

April 2, 2008 (Chicago) — A new meta-analysis of six randomized trials

involving the cyclooxygenase-2 (COX-2) inhibitor celecoxib (Celebrex,

Pfizer) should help direct physicians who still want to prescribe this

drug [1]. Dr D (Brigham and Women's Hospital, Boston,

MA) presented the findings of the cross-trial safety analysis at a

late-breaking trials session here at the American College of

Cardiology 57th Annual Scientific Session, and they were published

simultaneously in Circulation.

et al found differences in the risk of adverse cardiovascular

events based on the dose regimen of celecoxib and showed that those

with the highest baseline cardiovascular risk had the greatest risk of

celecoxib-related adverse events. " These data should provide comfort

in prescribing celecoxib to patients with very low cardiovascular

risk. It helps us to chose which patients we can feel safe about

giving celecoxib to, " said . " Similarly, we should be cautious

in prescribing celecoxib to patients who have elevated baseline

cardiovascular risk. Our data support the recent American Health

Association (AHA) scientific position statement suggesting that

physicians should prescribe the lowest doses of celecoxib possible,

especially in higher-risk patients. "

*****************************************************

Read the rest of the article here:

http://www.medscape.com/viewarticle/572407

--

Not an MD